Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial

CR4056 is a selective imidazoline-2 (I2) receptor ligand with potent analgesic activity in animal pain models. This proof-of-concept study tested CR4056 efficacy and safety in patients with knee osteoarthritis (OA) and different phenotypes.

Source: Osteoarthritis and Cartilage - September 13, 2019 Category: Rheumatology Authors: Lucio C. Rovati, Nadia Brambilla, Tomasz Blicharski, John Connell, Cristina Vitalini, Albino Bonazzi, Giampaolo Giacovelli, Federica Girolami, Massimo D ’Amato Source Type: research